BCT — Briacell Therapeutics Balance Sheet
0.000.00%
- CA$26.93m
- CA$19.46m
Annual balance sheet for Briacell Therapeutics, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2020 July 31st | C2021 July 31st | 2022 July 31st | 2023 July 31st | 2024 July 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | USG | USG | USG | USG |
Status: | fx Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.019 | 57.3 | 41 | 21.3 | 0.862 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.021 | 0.013 | 0.024 | 0.019 | 2.79 |
Prepaid Expenses | |||||
Total Current Assets | 0.239 | 57.8 | 42.3 | 26.9 | 3.65 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | — | — | — | — | 0.388 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 0.478 | 58 | 42.6 | 27.2 | 5.87 |
Accounts Payable | |||||
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 3.63 | 0.557 | 0.941 | 1.8 | 7.46 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 3.77 | 30.4 | 32.2 | 30.9 | 8.25 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -3.3 | 27.7 | 10.3 | -3.78 | -2.38 |
Total Liabilities & Shareholders' Equity | 0.478 | 58 | 42.6 | 27.2 | 5.87 |
Total Common Shares Outstanding |